Skip to content

Author

Arantza Azpilikueta

We have 3 of 69 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

CD137 agonists in mice suppress germinal center responses by increasing the immunosuppressive activity of follicular regulatory T-cells

Humoral immune responses rely on germinal center (GC) reactions to generate long-lasting antibody responses with affinity maturation. CD137 (4-1BB) agonists are known to exert inhibitory effects on B-cell responses; however, the underlying mechanisms remain unclear. Here, we show that agonistic anti-CD137 monoclonal an...

Ana Martínez-Riaño, Raquel Cuesta, Dayanna Salinas et al. · 0 citations
Aug 2026

Antibody-Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors.

Antibody-drug conjugates (ADCs) show clinical efficacy against several solid malignancies, inducing cytotoxic effects in malignant cells accompanied by changes in the composition of the tumor stroma. The therapeutic effects of some ADCs have been shown to be potentiated by combination with anti-PD(L)1 checkpoint inhibi...

Gabriel Gomis, Claudia Herrero, Saioa Arrieta-Aranzueque et al. · 1 citation
Open access Sep 2026

TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment

Evidence is provided for a key role of TNFR1, as expressed by malignant cells, in orchestrating a pro-tumor immunosuppressive environment through secondary inflammatory mediators through secondary inflammatory mediators.

Elixabet Bolaños, Lorena Cañas-Zabala, Irene Olivera et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.